PLX4032 was designed to target a very specific mutation, the BRAF v600e mutation, they screen patients for this mutation. It's not a matter of nexavar being a crappy multi kinase drug (to quote BTH's flippant remark), nexavar wasn't designed to hit that mutation.
Market Data 
Markets
AI
